


This article was downloaded by: [University at Buffalo (SUNY)]

On: 16 October 2008

Access details: Access Details: [subscription number 784375717]

Publisher Informa Healthcare

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Biomarkers

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713693137>

Clinical evaluation of the simultaneous determination of CA 15-3, CA 125 and sHER2 in breast cancer

Dejan Baski ^a; Petar Risti ^a; Snežana Mati ^a; Dragi Bankovi ^b; Suzana Popovi ^a; Nebojša Arsenijevi ^a

^a Institute of Microbiology and Immunology, Medical Faculty, Serbia ^b Faculty of Mathematics and Natural Sciences, University of Kragujevac, Serbia

First Published on: 12 July 2007

To cite this Article Baski, Dejan, Risti, Petar, Mati, Snežana, Bankovi, Dragi, Popovi, Suzana and Arsenijevi, Nebojša(2007)'Clinical evaluation of the simultaneous determination of CA 15-3, CA 125 and sHER2 in breast cancer',Biomarkers,12:6,657 — 667

To link to this Article: DOI: 10.1080/13547500701520563

URL: <http://dx.doi.org/10.1080/13547500701520563>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

Clinical evaluation of the simultaneous determination of CA 15-3, CA 125 and sHER2 in breast cancer

DEJAN BASKIĆ¹, PETAR RISTIĆ¹, SNEŽANA MATIĆ¹,
DRAGIĆ BANKOVIĆ², SUZANA POPOVIĆ¹, &
NEBOJŠA ARSENIJEVIĆ¹

¹*Institute of Microbiology and Immunology, Medical Faculty and* ²*Faculty of Mathematics and Natural Sciences, University of Kragujevac, Serbia*

Abstract

Objective We investigated serum levels of CA 15-3, sHER2 and CA 125, and their usefulness in the detection of metastatic disease in breast cancer patients.

Methods The levels of CA 15-3, sHER2 and CA 125 tumour markers were determined in 60 patients, 40 with localized and 20 with metastatic breast carcinoma. The control group consisted of 10 healthy women.

Results We found that, at the time of diagnosis, serum levels of all three tumour markers were elevated in patients with distant metastases, but of minute importance in the detection of any breast cancer. When the data for the individual markers were combined the overall sensitivity of metastases detection with all three markers improved. In this regard, 90% of patients with distant metastases had an increase in serum level of at least one of tested tumour markers. Similar results were obtained using receiver operating characteristic curve (ROC). Moreover, using ROC we defined cut-off values for metastasis detection for each of the tested markers.

Conclusion Our findings indicate that measurement of CA 15-3 serum values in conjunction with sHER2 and CA 15-3 can increase sensitivity in metastasis detection.

Keywords: Breast cancer, CA 15-3, sHER2, CA 125, serum levels

(Received 28 November 2006; accepted 19 June 2007)

Introduction

One of the major aims in cancer research has been to develop biochemical tests for aiding screening and early diagnosis, assessing prognosis, predicting response to therapy and monitoring patients. All of these tasks, as well as treatment decisions for individual breast cancer patients were frequently (virtually obligatorily) based on traditional pathological parameters or other tissue-based assays. However, all of these methods require tumour tissue and thus invasive procedures. Consequently, the possibility of using the circulating markers as a way to predict patients' outcomes is more desirable.

To date, no tumour marker has demonstrated significant benefits in randomized controlled trials of screening and early diagnosis in the general population.

Correspondence: Dejan Baskić, School of Medicine, University of Kragujevac, S. Markovica 69, 34000 Kragujevac, Serbia and Montenegro. Tel: + 381 34 331344. Fax: + 381 34 331345. E-mail: dejan.baskic@gmail.com

ISSN 1354-750X print/ISSN 1366-5804 online © 2007 Informa UK Ltd.
DOI: 10.1080/13547500701520563

